Foundayo Wins European Backing, but Lilly Still Needs Final Authorization

Eli Lilly's once-daily GLP-1 pill has cleared the main scientific review before a European launch. The European Medicines Agency's human medicines committee adopted a positive opinion for Foundayo on October 15, recommending authorization for weight management and type 2 diabetes in adults.

The recommendation covers adults with obesity, as well as adults who are overweight and have at least one related condition. It also covers adults with insufficiently controlled type 2 diabetes, either alone when metformin is inappropriate or in combination with other medicines.

Foundayo's active ingredient is orforglipron, an oral GLP-1 receptor agonist. The EMA said the medicine produced clinically relevant improvements in blood-sugar control and had a beneficial effect on body weight when used with diet and physical activity. The most common adverse effects were gastrointestinal, including nausea, vomiting and diarrhea.

A recommendation is not the final approval

The next step is a legally binding decision from the European Commission. The Commission usually follows the committee's scientific opinion, but Lilly cannot market the medicine across the European Union on the basis of the recommendation alone. Lilly also has not provided a confirmed European launch date.

The commercial opportunity is meaningful because an oral pill may reach patients who do not want injections and can be easier to distribute at scale. Foundayo is already approved in the United States, and Lilly reported $98 million of second-quarter revenue for the medicine. That remains small beside Mounjaro and Zepbound, which together produced nearly $14.9 billion in the quarter.

For Lilly investors, the regulatory progress adds another route to growth but does not remove execution risk. The key questions are how quickly the Commission acts, what label and reimbursement terms national markets adopt, and whether Foundayo expands the treated population rather than mostly shifting patients from Lilly's injectable drugs.

National reimbursement decisions will also determine uptake because a positive EU authorization does not guarantee identical access or pricing across member states.